Tertius News is an AI-native newsroom: an AI model reads the linked source articles below and extracts what each outlet reported, so you can compare their coverage side by side. How this works →

One-Time Gene Editing Cuts Cholesterol by Half for Over a Year, Early Data Shows

A pilot study with 15 patients suggests a one-time CRISPR-Cas9 infusion targeting the ANGPTL3 gene can lower LDL cholesterol and triglycerides by about half for at least a year. While experts call the results promising, they caution that larger trials are needed to confirm durability and safety.

By Tertius News AI Desk 2 distinct · 3 mastheads · 3 articles Version 1 Coverage Aug 23–28, 2026 Published 1d ago

A one-time infusion that edits a single gene has been shown to lower dangerously high cholesterol by approximately 50% for a full year, according to results published in The New England Journal of Medicine. The treatment, which uses CRISPR-Cas9 to cut the ANGPTL3 gene in liver cells, was evaluated in a pilot study involving 15 patients with severely elevated cholesterol that did not respond to standard medication.

A durable effect

The updated data, released Friday in NEJM, shows that patients who received the highest dose of the experimental therapy—four of the 15 participants—sustained reductions in both LDL cholesterol and triglycerides. LDL, often called "bad" cholesterol, is a major contributor to heart disease, while triglycerides are another blood fat linked to cardiovascular risk. At the one-year mark, LDL levels had fallen by approximately 53%, and triglycerides were nearly 48% lower.

"This new data is essentially saying that the decreases in LDL cholesterol and triglycerides we saw at 60 days after treatment have lasted over a year," said Dr. Luke Laffin, a preventive cardiologist at Cleveland Clinic's Heart, Vascular & Thoracic Institute and lead author of the study. "In people who took the highest dose, the reduction seems durable and safe."

The study was designed primarily to test safety across five dose levels, not to measure long-term outcomes. Side effects were described as minimal, mostly irritation at the infusion site. One patient experienced a spinal disk herniation, and another had a temporary increase in liver enzymes. A death occurred six months after infusion in one participant, but investigators determined it was unrelated to the treatment.

A 'game changer' for some

The findings have sparked optimism among cardiologists. "If you'd asked me 15 years ago if we could have done something like this, I would have thought you were crazy," said Dr. Steven Nissen, chief academic officer of the Sydell and Arnold Miller Family Heart, Vascular & Thoracic Institute at Cleveland Clinic and senior study author.

If confirmed in larger trials, the approach could be transformative for younger patients with inherited forms of high cholesterol. "The procedure could be a game changer for young people with severe disease," said Nissen. A new clinical trial with up to 40 participants receiving the highest dose is already underway in the US and Australia.

Promise and unanswered questions

Researchers and doctors stress that substantial hurdles remain. The therapy must pass rigorous phase 2 and phase 3 trials and receive FDA approval before it could be widely available. Long-term effects of permanently altering a gene are unknown, and durability over decades remains an open question. Cost and access are also major barriers, though experts note that prices for similar therapies have historically declined over time.

Dr. Pradeep Natarajan of Massachusetts General Hospital and Harvard Medical School, who was not involved in the study, called the results exciting but cautioned that larger studies are needed to confirm benefits and monitor risks over a longer period.

"For cardiovascular medicine, this would represent a profound shift: from managing a risk factor year after year to potentially altering one of its underlying causes," said a commentary accompanying the NEJM publication.

How each outlet told it

A framing line is our reading of that outlet's own text — an interpretation, not a quotation and not a fact we assert. Check it against what the outlet published.

CNN — World

Framing: Emphasizes the potential longevity of the treatment effect: 'Gene editing may lower bad cholesterol for life' — Optimistic and enthusiastic, while also noting limitations and ongoing research.

as of Aug 28, 2026, 3:30 PM UTC

Facts Included:

A one-time snip of a key gene lowered heart-clogging cholesterol by about 50% over an entire year with no adverse effects, scientists have reported.
The overwhelmingly positive results were found in four people who had taken the highest dose of the experimental treatment during a pilot study published in The New England Journal of Medicine in November 2025.
That study was extremely small — only 15 patients with dangerously high cholesterol that did not respond to medication.
An update on the study, published Friday in NEJM, appears to answer the question: Does the intervention last?
LDL cholesterol is known as 'bad' cholesterol; triglycerides are a different type of fat in the blood.
If larger clinical trials show similar results, the procedure could be a game changer for young people with severe disease.
Researchers estimate only half of people take their cholesterol meds more than 80% of the time, and between 33% to 50% discontinue their statin medication within a year after starting treatment.
The idea for a gene-editing treatment came from an unusual source — a genetic mutation in the ANGPTL3 gene.
In the study, one group of people received a tiny dose of 0.1 milligrams per kilogram, while others received 0.3, 0.6, 0.7 and 0.8 milligrams per kilogram.
People who got the highest dose had an average 55% decrease in triglycerides and nearly 50% reduction in LDL cholesterol at two months; at one year, triglycerides were nearly 48% lower and cholesterol dropped by almost 53%.
Medications available today can already lower LDL cholesterol to the levels found in the study.
Side effects of the initial treatment were minimal, mostly irritation at infusion sites.
One person died six months after the infusion; Nissen said, 'We don’t think that his death has any implications to the study at all.'
A new clinical trial, with up to 40 people receiving the highest dose, is underway in the US and Australia.
Research must move to phase 2 and phase 3 clinical trials and be approved by the FDA before the procedure could be more widely available.

Read the source article →

Gulf Coast News and Weather

Framing: Emphasizes the potential of gene editing to permanently lower cholesterol

as of Aug 28, 2026, 7:16 PM UTC

Facts Included:

A one-time snip of a key gene lowered heart-clogging cholesterol by about 50% over an entire year with no adverse effects.
The results were found in four people who had taken the highest dose of the experimental treatment.
The pilot study was published in The New England Journal of Medicine in November 2025.
The study included only 15 patients with dangerously high cholesterol that did not respond to medication.
The treatment is a CRISPR-Cas9 infusion that targets the ANGPTL3 gene in the liver.
At one year, patients who got the highest dose (0.8 mg/kg) had average triglyceride levels nearly 48% lower and cholesterol levels dropped by almost 53%.
Side effects were minimal, mostly irritation at infusion sites; one person had a spinal disk herniation, another had a temporary increase in liver enzymes.
One person died six months after infusion; the death was considered unrelated to the study.
A new clinical trial with up to 40 people receiving the highest dose is underway in the US and Australia.
The procedure must pass phase 2 and phase 3 clinical trials and FDA approval before wider availability.

Read the source article →

THE WEEK

Framing: Emphasizes the potential of a single treatment to replace lifelong medication, framing it as a hopeful scientific advancement. — The tone is cautiously optimistic, acknowledging the potential while underscoring the need for more research and addressing practical barriers.

as of Aug 23, 2026, 2:46 AM UTC

Facts Included:

The article discusses a potential single-treatment gene therapy targeting the PCSK9 gene to lower LDL cholesterol.
It notes that current treatments require daily or repeated dosing and face issues with adherence and response.
It reports that a study published in The New England Journal of Medicine in May 2026 involved 35 participants.
The article states the therapy reduced PCSK9 levels by up to 88% and LDL cholesterol by up to 62%.
It mentions the reduction in LDL was sustained for at least one year at the highest dose.
It notes that the trial was early-stage and focused on safety and biological effects, not long-term outcomes like heart attacks or strokes.
It acknowledges uncertainties about durability over decades and potential unforeseen risks from permanent DNA alteration.
It highlights cost and access as major hurdles, while noting that costs of such therapies have historically decreased over time.
It references that cardiovascular disease is a major health challenge in India, with nearly 29 lakh deaths estimated in 2021, and often develops at younger ages.

Read the source article →

What was claimed, and who backed it

AI-extracted; can misattribute a claim — see Methodology.

Each row is one claim, attributed to the outlet whose wording states it most clearly. Confidence rates how directly the source text states the claim — explicit and unhedged rates high; hedged, pieced-together, or internally inconsistent statements rate lower. It does not measure whether the claim is true. Status is Contested when two claims on this page negate each other; otherwise it counts the distinct outlets we found asserting it — so a single-source claim can still show high confidence, and a multi-source claim can show medium. Every one of those outlets is named beside the status, so you can check the count against the list. For claims extracted before we began storing that list, the row says so: it names the outlet the claim is quoted from and states that we have not recorded which outlets backed it. Outlets wrote at different times, so a figure that evolves — a casualty count, for example — can legitimately differ between rows; check the "as of" time next to each claim's source.

Claim	Confidence	Status
ClaimThe results were found in four people who had taken the highest dose of the experimental treatment.	ConfidenceHigh	StatusSingle-source via Gulf Coast News and Weather as of Aug 28, 2026, 7:16 PM UTC
ClaimThe study included only 15 patients with dangerously high cholesterol that did not respond to medication.	ConfidenceHigh	StatusSingle-source via Gulf Coast News and Weather as of Aug 28, 2026, 7:16 PM UTC
ClaimThe treatment is a CRISPR-Cas9 infusion that targets the ANGPTL3 gene.	ConfidenceHigh	StatusSingle-source via Gulf Coast News and Weather as of Aug 28, 2026, 7:16 PM UTC
ClaimAt one year, patients on the highest dose had average triglyceride levels nearly 48% lower and LDL cholesterol levels dropped by almost 53%.	ConfidenceHigh	StatusSingle-source via Gulf Coast News and Weather as of Aug 28, 2026, 7:16 PM UTC

Transparency & Audit Trail

2 distinct · 3 mastheads · 3 articles consulted: CNN — World, Gulf Coast News and Weather, THE WEEK 4 claims extracted Version 1 Written 2026-08-28